Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\VSpNMUUN3ME2wMlAxODB|MUeg{txO MYLTRW5ITVJ?
SK-MEL-30 NGLHbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzLTWM2OD1yLkCwNFM2PSEQvF2= NHzSXoVUSU6JRWK=
NALM-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7mOm5KSzVyPUCuNFAxOzV4IN88US=> NXriVIk5W0GQR1XS
KYSE-450 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[zSGlEPTB;MD6wNFA1PjlizszN M1XYR3NCVkeHUh?=
BHY NYTWUY5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT1OI9{UUN3ME2wMlAxODZyMTFOwG0> MXjTRW5ITVJ?
GR-ST NEjRVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSweFZjUUN3ME2wMlAxODZ2ODFOwG0> Mn\XV2FPT0WU
786-0 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXYTWM2OD1yLkCwNFc4PiEQvF2= MYrTRW5ITVJ?
C-33-A M3PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXDTWM2OD1yLkCwNFg1QCEQvF2= NIPnc49USU6JRWK=
BHT-101 NVr0[GFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISzRnNKSzVyPUCuNFAyODZizszN NGHzUWpUSU6JRWK=
EB2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7ZVXl2UUN3ME2wMlAxOTF6IN88US=> MmHqV2FPT0WU
G-361 M2DW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVizeJdwUUN3ME2wMlAxOTJ2IN88US=> MVnTRW5ITVJ?
KE-37 M3fne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHETWM2OD1yLkCwNVI5KM7:TR?= NWPQcJp2W0GQR1XS
MHH-PREB-1 NYTxUWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrzeXZKSzVyPUCuNFAyPCEQvF2= MWrTRW5ITVJ?
MCF7 M{PW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGyTWM2OD1yLkCwNVU6KM7:TR?= MkH4V2FPT0WU
LOUCY NIPGUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH2XGhKSzVyPUCuNFAyPzVizszN MmP3V2FPT0WU
EW-7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH4OG5VUUN3ME2wMlAxOTd3IN88US=> NU\Le2c6W0GQR1XS
KYSE-510 NFHaXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjHT2RKSzVyPUCuNFAzOzNizszN M1;pPHNCVkeHUh?=
SK-MEL-3 M{fjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTBVXZnUUN3ME2wMlAxOjZ2IN88US=> MnnVV2FPT0WU
HAL-01 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;QPGlEPTB;MD6wNFI6PyEQvF2= NX:3WmdLW0GQR1XS
HCC2998 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULSZlAzUUN3ME2wMlAxOzN3IN88US=> M1rIPXNCVkeHUh?=
A375 NELxc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nVdmlEPTB;MD6wNFM2KM7:TR?= Ml;1V2FPT0WU
MZ7-mel MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f0V2lEPTB;MD6wNFM6QSEQvF2= MXTTRW5ITVJ?
SH-4 NIDVXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEC0NVch|ryP NFzwd3NUSU6JRWK=
HT-144 NWP0c4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHxXmxKSzVyPUCuNFA1OyEQvF2= MUPTRW5ITVJ?
KYSE-140 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\nVWFKSzVyPUCuNFA1OzVizszN MkC2V2FPT0WU
PSN1 M1qxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXKc2VRUUN3ME2wMlAxPDZ5IN88US=> NHfHfGVUSU6JRWK=
COLO-679 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEC0PVgh|ryP NGrvZm1USU6JRWK=
SW620 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELJN2ZKSzVyPUCuNFA2OTFizszN M4fYd3NCVkeHUh?=
HGC-27 NEX1UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEC1NlQh|ryP MWDTRW5ITVJ?
IGROV-1 NGH4R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP0OpZjUUN3ME2wMlAxPiEQvF2= NGHoXpFUSU6JRWK=
IGR-1 M13iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrWV5FKSzVyPUCuNFA3ODFizszN NEX6XGRUSU6JRWK=
EW-1 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nrW2lEPTB;MD6wNFY2OSEQvF2= NYjWPFMxW0GQR1XS
769-P MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTFeFBKSzVyPUCuNFA3PzhizszN MX3TRW5ITVJ?
HN M1vWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTTTI5pUUN3ME2wMlAxPjd7IN88US=> NWDPbodmW0GQR1XS
SIG-M5 NUnWeoVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXu[Vl3UUN3ME2wMlAxPzFizszN M3fIcXNCVkeHUh?=
IST-MEL1 NETabVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvGZnlKSzVyPUCuNFA5OThizszN NXnQd5VuW0GQR1XS
ST486 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEC4NlUh|ryP MYTTRW5ITVJ?
ES7 M1:ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1riXmlEPTB;MD6wNFg1PiEQvF2= NHzQN2ZUSU6JRWK=
GAK NXfVPVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13tOWlEPTB;MD6wNFg1QCEQvF2= M{TCZ3NCVkeHUh?=
BB30-HNC M4DjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEC4OVgh|ryP NHi4dmJUSU6JRWK=
IPC-298 NGXPUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6yUJdyUUN3ME2wMlAxQTJ5IN88US=> M12xe3NCVkeHUh?=
NKM-1 M{XRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XofmlEPTB;MD6wNFk4OiEQvF2= M{\0PXNCVkeHUh?=
RKO MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEGwOFQh|ryP MXPTRW5ITVJ?
ACN MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEGxN|Eh|ryP MojFV2FPT0WU
SW1417 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEGyNlUh|ryP MmnaV2FPT0WU
SR MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7tcZBsUUN3ME2wMlAyOjN3IN88US=> M2PaZXNCVkeHUh?=
SNG-M MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfkb4w3UUN3ME2wMlAyOzF5IN88US=> NFPVbXVUSU6JRWK=
CAL-12T NVuxTW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXyR3VKSzVyPUCuNFE{PDZizszN MXTTRW5ITVJ?
HSC-3 M2PJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEGzOVUh|ryP MlPsV2FPT0WU
DOHH-2 NH64Z5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2POW2lEPTB;MD6wNVQyOiEQvF2= NYjN[4N2W0GQR1XS
NB69 NVXvS5QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXzTWM2OD1yLkCxOVY2KM7:TR?= MknkV2FPT0WU
LC-2-ad NIPXXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LyOWlEPTB;MD6wNVU5OSEQvF2= MX\TRW5ITVJ?
RVH-421 NGnVdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jBVmlEPTB;MD6wNVY4PCEQvF2= MWnTRW5ITVJ?
TGW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHo[2FKSzVyPUCuNFE4OzlizszN NWXMUpB3W0GQR1XS
HCC1569 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3sTWM2OD1yLkCxO|k4KM7:TR?= MX3TRW5ITVJ?
CAL-85-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEG4N|Ih|ryP M1HG[3NCVkeHUh?=
RPMI-8402 NIC5XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfwd4VKSzVyPUCuNFE5PThizszN NUj0WoVrW0GQR1XS
THP-1 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPKNHhtUUN3ME2wMlAyQTl6IN88US=> MX7TRW5ITVJ?
ONS-76 NWrDNJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf4ZlZlUUN3ME2wMlAzODN4IN88US=> M4nmZnNCVkeHUh?=
A2780 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTJTWM2OD1yLkCyNFc6KM7:TR?= NWTQOnpRW0GQR1XS
RPMI-2650 NWrHUlU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zoVWlEPTB;MD6wNlI6PiEQvF2= NF;sOmNUSU6JRWK=
MEL-HO M4P4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zZN2lEPTB;MD6wNlM1QCEQvF2= M2rTVHNCVkeHUh?=
MC-CAR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvBToxKSzVyPUCuNFI{PTZizszN NXrKTXViW0GQR1XS
HSC-2 NF\sTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEK0OlYh|ryP NYq2bnFWW0GQR1XS
MEL-JUSO M2fpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEK0O|Mh|ryP MVnTRW5ITVJ?
CAL-62 M3\VbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEK2NFIh|ryP Mn:wV2FPT0WU
DMS-273 NI\V[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDT[21KUUN3ME2wMlAzQDR5IN88US=> NHLIU2VUSU6JRWK=
S-117 M{LPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nkeGlEPTB;MD6wNlkxPiEQvF2= MlTpV2FPT0WU
SUP-T1 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LKPGlEPTB;MD6wNlk1QSEQvF2= M2DySHNCVkeHUh?=
MZ2-MEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7CTWM2OD1yLkCyPVU6KM7:TR?= NIHMVm5USU6JRWK=
KYSE-270 NGW2N|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEK5O|Yh|ryP MWDTRW5ITVJ?
CMK M4\DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEOwNlMh|ryP NUfI[YRMW0GQR1XS
8505C NF72UoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jpcmlEPTB;MD6wN|A1KM7:TR?= MnvRV2FPT0WU
NUGC-3 M4\GbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLWTWM2OD1yLkCzNFQ5KM7:TR?= M3X3VHNCVkeHUh?=
A101D MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEOwOVUh|ryP MVPTRW5ITVJ?
G-401 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEOwPVMh|ryP MljuV2FPT0WU
OVCAR-8 NVqyZ2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TxfmlEPTB;MD6wN|ExPyEQvF2= NFzVOnlUSU6JRWK=
IMR-5 M3G4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6xTWM2OD1yLkCzNlQ1KM7:TR?= M1jwNXNCVkeHUh?=
DoTc2-4510 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfhTWM2OD1yLkCzN|k{KM7:TR?= NXvRTI1UW0GQR1XS
HOS M1\4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0WnRKSzVyPUCuNFM1PzNizszN M2m5NnNCVkeHUh?=
HEC-1 NFn2UJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEO2PEDPxE1? M4\QPXNCVkeHUh?=
SW756 M{fZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEO4NlEh|ryP NFe4W4FUSU6JRWK=
NCI-H64 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEO4OFIh|ryP Moq5V2FPT0WU
EW-16 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHUR|F[UUN3ME2wMlA{QTB7IN88US=> MWHTRW5ITVJ?
CAL-51 NE\pdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHQPY1KSzVyPUCuNFQxODVizszN MknBV2FPT0WU
KYSE-150 NVvpUnhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLtfGR[UUN3ME2wMlA1ODFzIN88US=> M4O4RXNCVkeHUh?=
SW1710 NVryS2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{La[mlEPTB;MD6wOFAyQCEQvF2= M3fDdnNCVkeHUh?=
HuP-T4 MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn1c2tbUUN3ME2wMlA1OTF6IN88US=> MUTTRW5ITVJ?
LB373-MEL-D MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rhZWlEPTB;MD6wOFI{OiEQvF2= NUXuZodzW0GQR1XS
EW-13 NIPySYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMES0NFYh|ryP M4ToTXNCVkeHUh?=
HT-29 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorJTWM2OD1yLkC0OFkh|ryP NG\6U|JUSU6JRWK=
SCC-25 NUDXUG1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMES0PVQh|ryP M{\4VHNCVkeHUh?=
REH MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMES2N|Uh|ryP NI\rNlhUSU6JRWK=
L-363 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSyTWM2OD1yLkC0Olc6KM7:TR?= NGXyeoFUSU6JRWK=
NCI-H1770 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf1ZY1KSzVyPUCuNFQ3QTdizszN NUHBV5RTW0GQR1XS
CHL-1 NXnTb29xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfaRXlsUUN3ME2wMlA1QDV5IN88US=> MWDTRW5ITVJ?
ES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CzcmlEPTB;MD6wOFg5PSEQvF2= MUPTRW5ITVJ?
SCC-15 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHI[5hSUUN3ME2wMlA1QTB{IN88US=> MW\TRW5ITVJ?
MRK-nu-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Ud2lEPTB;MD6wOFk{PiEQvF2= NIPTNI1USU6JRWK=
PF-382 NFy4OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;HZ5lSUUN3ME2wMlA1QTN7IN88US=> NVTncFg{W0GQR1XS
COLO-680N M{PtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH2ZYlNUUN3ME2wMlA2ODR5IN88US=> MWrTRW5ITVJ?
LK-2 NELzR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEWwOlMh|ryP NYLTbotUW0GQR1XS
NCI-H2342 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXmN2tKSzVyPUCuNFUyOTdizszN MUHTRW5ITVJ?
HMV-II M3GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HpXGlEPTB;MD6wOVI{QSEQvF2= NYTsNFI{W0GQR1XS
PC-14 NIrpXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEWyOVIh|ryP MXjTRW5ITVJ?
COLO-320-HSR MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEWyPFkh|ryP NXPaSFZIW0GQR1XS
697 NFXHZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jQOmlEPTB;MD6wOVMzOyEQvF2= M2TQXXNCVkeHUh?=
NEC8 M3Lwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj0TWM2OD1yLkC1OVkh|ryP NGTyWIJUSU6JRWK=
LCLC-97TM1 M4L0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vlfWlEPTB;MD6wOVU6PCEQvF2= Mn34V2FPT0WU
Daoy NETTN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEW2NVYh|ryP MlvQV2FPT0WU
ETK-1 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13NemlEPTB;MD6wOVY4OiEQvF2= NHP4NIxUSU6JRWK=
A388 NETFb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofDTWM2OD1yLkC1Olk2KM7:TR?= NY[5fXZ5W0GQR1XS
COLO-205 M{jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX72SXN7UUN3ME2wMlA2PzF4IN88US=> MVPTRW5ITVJ?
SK-PN-DW NY\iZpRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPH[o9KSzVyPUCuNFU4OjlizszN MkjCV2FPT0WU
SF268 NIe5VINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;NbXJKSzVyPUCuNFU4PTZizszN NYTBfHJuW0GQR1XS
OCI-AML2 M4XY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TFfWlEPTB;MD6wOVc4PyEQvF2= NIHxeFdUSU6JRWK=
GAMG MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTVZ5JQUUN3ME2wMlA2QCEQvF2= Mn3HV2FPT0WU
BCPAP MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEW4PVIh|ryP MnWyV2FPT0WU
BC-1 M2O1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwME[wNlIh|ryP NInXNZhUSU6JRWK=
IA-LM M1KxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInlfnpKSzVyPUCuNFYxPTNizszN MUDTRW5ITVJ?
NCI-H1299 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwME[xN{DPxE1? MUTTRW5ITVJ?
COR-L23 M3LU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwME[xN|Qh|ryP NUfBd|h6W0GQR1XS
KYSE-180 M1zBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPyem45UUN3ME2wMlA3OTR{IN88US=> M4THe3NCVkeHUh?=
LOXIMVI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDLUHJYUUN3ME2wMlA3OTh6IN88US=> NVjPWIh3W0GQR1XS
BL-41 MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7Rd2pKSzVyPUCuNFYzOTlizszN NWW1cVdJW0GQR1XS
BL-70 NF21ZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwME[zNFIh|ryP M1\EeXNCVkeHUh?=
NOS-1 NIfnZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHOOoFKSzVyPUCuNFY1OTFizszN MXvTRW5ITVJ?
NB13 NUXndZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH5RVdKSzVyPUCuNFY1OjFizszN NFmzUXBUSU6JRWK=
CAL-27 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;oTWdMUUN3ME2wMlA3PDZ2IN88US=> M{\vZ3NCVkeHUh?=
CA46 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITkO5JKSzVyPUCuNFY2OzdizszN MUHTRW5ITVJ?
SW962 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwME[1Olkh|ryP NHzQO4xUSU6JRWK=
NCI-H226 NXe1O4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjyTWM2OD1yLkC2OlMzKM7:TR?= MVLTRW5ITVJ?
KYSE-70 NHi0bllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnafnlmUUN3ME2wMlA3QTR3IN88US=> NGrpZ3BUSU6JRWK=
Daudi NHLac3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK0e3ZOUUN3ME2wMlA4ODhzIN88US=> NVf0R|BZW0GQR1XS
SW626 NXPaWXpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Md4gzUUN3ME2wMlA4OjB2IN88US=> MlW2V2FPT0WU
ESS-1 NI\vZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEeyOFYh|ryP M1PUfXNCVkeHUh?=
YT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEezOFUh|ryP MlnYV2FPT0WU
P12-ICHIKAWA NITM[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTqTWM2OD1yLkC3N|Q6KM7:TR?= M3jHSnNCVkeHUh?=
BxPC-3 M3fzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfMTWM2OD1yLkC3OFU5KM7:TR?= MUTTRW5ITVJ?
CTV-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEe1NVch|ryP NEH5PY5USU6JRWK=
MLMA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfjWpAyUUN3ME2wMlA4PTN2IN88US=> M{HzNXNCVkeHUh?=
WSU-NHL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e2WWlEPTB;MD6wO|U2PCEQvF2= M3ryWHNCVkeHUh?=
CTB-1 M2P6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDwc3pKSzVyPUCuNFc2QDhizszN NGTMeJVUSU6JRWK=
MMAC-SF NFP1bZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWyTWM2OD1yLkC3OlY5KM7:TR?= NFjMU5VUSU6JRWK=
8-MG-BA Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEe4NFEh|ryP NUW2SZZNW0GQR1XS
NCI-H358 Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj2[GxKSzVyPUCuNFc5PzlizszN MnXkV2FPT0WU
BFTC-905 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFSYxCUUN3ME2wMlA4QTB7IN88US=> MUnTRW5ITVJ?
NCI-H727 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HVWmlEPTB;MD6wPFA2OyEQvF2= M2S1UnNCVkeHUh?=
CHP-212 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TSVGlEPTB;MD6wPFA6PSEQvF2= MWjTRW5ITVJ?
HOP-62 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEiyOFUh|ryP MYTTRW5ITVJ?
CESS MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEiyOlkh|ryP NWjYXHhuW0GQR1XS
HuCCT1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm0SlBKSzVyPUCuNFg{OzNizszN NXnYR3NPW0GQR1XS
DEL NVG3ZXdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEizOFch|ryP M3K3[XNCVkeHUh?=
5637 NHX3R5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;E[IJKSzVyPUCuNFg{PjdizszN NXqxNGRIW0GQR1XS
RS4-11 NXH2cIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XlfGlEPTB;MD6wPFQ6PyEQvF2= M2ToXnNCVkeHUh?=
KURAMOCHI Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHoOWltUUN3ME2wMlA5PTB7IN88US=> MXXTRW5ITVJ?
A427 NUO3NlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\iN2pKSzVyPUCuNFg2OTJizszN NXrI[WN4W0GQR1XS
A3-KAW NECzOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEi1OlYh|ryP MYrTRW5ITVJ?
LS-123 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnCV|FyUUN3ME2wMlA5PzF7IN88US=> MoDtV2FPT0WU
LoVo MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVra[4Q2UUN3ME2wMlA5PzJizszN MkTSV2FPT0WU
PA-1 M4LKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjaXGJuUUN3ME2wMlA5PzZ7IN88US=> MnvGV2FPT0WU
CP50-MEL-B NYLiXml{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK5TWM2OD1yLkC4O|k{KM7:TR?= MoPZV2FPT0WU
A431 NUfrS4tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3uZYVKSzVyPUCuNFg5ODFizszN NXXTTpNJW0GQR1XS
HCT-116 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XoR2lEPTB;MD6wPFgxOiEQvF2= Mn3vV2FPT0WU
A4-Fuk NHfnOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK5TWM2OD1yLkC4PVQ4KM7:TR?= MX3TRW5ITVJ?
RPMI-6666 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O5fWlEPTB;MD6wPFk3PyEQvF2= M2jWS3NCVkeHUh?=
Calu-6 M{PGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonGTWM2OD1yLkC5NFI6KM7:TR?= NV\5[WMxW0GQR1XS
KMOE-2 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn2UlNTUUN3ME2wMlA6ODN7IN88US=> NV:zbmFiW0GQR1XS
A704 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S1TmlEPTB;MD6wPVE2KM7:TR?= Mo\rV2FPT0WU
HO-1-N-1 NEP2VJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\vTWlEPTB;MD6wPVI1QSEQvF2= MlvQV2FPT0WU
NCI-H2122 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuwUZJWUUN3ME2wMlA6Ozd6IN88US=> NFfGZYlUSU6JRWK=
U-698-M NHvPcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTGS|kxUUN3ME2wMlA6PDB7IN88US=> NXzWVW9yW0GQR1XS
IST-SL2 M2HzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofrTWM2OD1yLkC5OFY5KM7:TR?= M{nCR3NCVkeHUh?=
TE-10 NHWxOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEm1PFQh|ryP NX30WpZmW0GQR1XS
PANC-03-27 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO1TWM2OD1yLkC5OlcyKM7:TR?= MojwV2FPT0WU
KYSE-410 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEm3PVch|ryP MUPTRW5ITVJ?
TE-8 NXj3UJQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX0U2JKSzVyPUCuNFk5QDVizszN MVHTRW5ITVJ?
MN-60 NV\Edno2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEm4PVch|ryP M4D6[XNCVkeHUh?=
NCI-H460 M4r0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfjSGFKSzVyPUCuNVAxQSEQvF2= M1\KVXNCVkeHUh?=
LB771-HNC MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ftcmlEPTB;MD6xNFI2PSEQvF2= MnjpV2FPT0WU
ES4 NGrnTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGyRmRKSzVyPUCuNVAzPjRizszN NEi1Z2ZUSU6JRWK=
HUTU-80 NIT1flFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn60TWM2OD1yLkGwN|Y2KM7:TR?= MYXTRW5ITVJ?
647-V MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jnS2lEPTB;MD6xNFQxQCEQvF2= MV\TRW5ITVJ?
HTC-C3 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPQdoN4UUN3ME2wMlExPDN{IN88US=> MnX0V2FPT0WU
NTERA-S-cl-D1 M4Hhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULGVWY2UUN3ME2wMlExPDR6IN88US=> Mmr0V2FPT0WU
A2058 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMUC2OVUh|ryP MmfYV2FPT0WU
MZ1-PC NEDvO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUC4N{DPxE1? NHHvdFJUSU6JRWK=
J82 NYCwTnFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfNdpRKSzVyPUCuNVA5QDRizszN Mn7oV2FPT0WU
ARH-77 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUGg{txO NYD3ZWQ1W0GQR1XS
Ca9-22 NInlR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHpTWM2OD1yLkGxNVI5KM7:TR?= NYDRSldNW0GQR1XS
NCI-H1648 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX34UnhXUUN3ME2wMlEyOjh4IN88US=> NVLQSVNxW0GQR1XS
MC116 M4LX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvO[YtqUUN3ME2wMlEyOzN5IN88US=> MWTTRW5ITVJ?
EoL-1-cell MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTWdFBKSzVyPUCuNVE1PjdizszN NYricI9EW0GQR1XS
PANC-10-05 NXXtWollT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPqb281UUN3ME2wMlEyPDlzIN88US=> MUfTRW5ITVJ?
SF539 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG0TWM2OD1yLkGxOlE3KM7:TR?= M4LBcnNCVkeHUh?=
ES8 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD1yLkGxOlM{KM7:TR?= NE\MNJhUSU6JRWK=
NCI-H810 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvJSW9KSzVyPUCuNVE3PjRizszN MlHXV2FPT0WU
J-RT3-T3-5 M1\CZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y2PGlEPTB;MD6xNVc2KM7:TR?= M{D6WHNCVkeHUh?=
NY Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rZ[GlEPTB;MD6xNVgyPyEQvF2= NWjEVow4W0GQR1XS
NCI-SNU-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1eIw3UUN3ME2wMlEzOTR6IN88US=> MoDIV2FPT0WU
EFM-19 NGm0R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYTWM2OD1yLkGyN|c1KM7:TR?= M17NRXNCVkeHUh?=
HCC1806 M1HITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnSd3N7UUN3ME2wMlEzOzh|IN88US=> MXrTRW5ITVJ?
HCE-T NWXvbY17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfQTWM2OD1yLkGyOVMyKM7:TR?= MoKzV2FPT0WU
HT-1376 M3TKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfUcmFKSzVyPUCuNVI3PjhizszN M2fCUnNCVkeHUh?=
BE-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;BU2lEPTB;MD6xNlg3PiEQvF2= MX3TRW5ITVJ?
NCI-H520 NEfPWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\sTWM2OD1yLkGyPFY4KM7:TR?= Ml3pV2FPT0WU
SK-MES-1 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PRWmlEPTB;MD6xNlkyOyEQvF2= MWTTRW5ITVJ?
SNU-423 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUK5NVQh|ryP NXjkXmh1W0GQR1XS
Ramos-2G6-4C10 NV3ZRoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3RfFJKSzVyPUCuNVI6OTZizszN NFi2PZNUSU6JRWK=
EW-18 NVLJWpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;o[mpjUUN3ME2wMlE{ODJ4IN88US=> MlfWV2FPT0WU
NCI-H2087 NI\UUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjJTWM2OD1yLkGzNFI4KM7:TR?= NUT2fXI4W0GQR1XS
COLO-792 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDaN3JLUUN3ME2wMlE{OTZ3IN88US=> NFLZS3RUSU6JRWK=
QIMR-WIL NXz5T|BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMUOyNlMh|ryP NEDl[ndUSU6JRWK=
ACHN NV7RfpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TxPGlEPTB;MD6xN|I1PyEQvF2= NYrEfmdZW0GQR1XS
RPMI-8866 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\VTWM2OD1yLkGzNlYyKM7:TR?= MlLCV2FPT0WU
SK-LU-1 NUPUb3dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnRdYRKSzVyPUCuNVM1PDlizszN M37ve3NCVkeHUh?=
SK-UT-1 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6ySoZKSzVyPUCuNVM3OjhizszN MoPQV2FPT0WU
MFE-296 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jVdWlEPTB;MD6xN|g3PCEQvF2= M1zmO3NCVkeHUh?=
RD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPlfXJ3UUN3ME2wMlE{QTl5IN88US=> MlP1V2FPT0WU
LS-411N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvaNGVKSzVyPUCuNVQzQTVizszN MXzTRW5ITVJ?
NCI-H747 NYTKeG56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13XS2lEPTB;MD6xOFMh|ryP NVfvWGdvW0GQR1XS
ES6 M1nmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMUSzOkDPxE1? MlnXV2FPT0WU
TE-1 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljBTWM2OD1yLkG0OFA4KM7:TR?= NH\xcWhUSU6JRWK=
SJSA-1 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUS3NFch|ryP MmX6V2FPT0WU
NCI-H1355 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUWyPVMh|ryP MnXMV2FPT0WU
HEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M173e2lEPTB;MD6xOVQ1PyEQvF2= NFi5bmhUSU6JRWK=
639-V M4Czbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXtUINKSzVyPUCuNVU2QTZizszN M2DQcXNCVkeHUh?=
AN3-CA M1KyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMUW2N|kh|ryP NFLTfYdUSU6JRWK=
SK-MEL-2 M2[wZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknvTWM2OD1yLkG1OlY5KM7:TR?= MXrTRW5ITVJ?
SW872 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPvb2lKSzVyPUCuNVYxPDJizszN NIX3[IlUSU6JRWK=
DU-4475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMU[xOlIh|ryP M{HzfnNCVkeHUh?=
YKG-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMU[yO|Mh|ryP MkLQV2FPT0WU
GT3TKB NUfDUVlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj3TWM2OD1yLkG2Nlg{KM7:TR?= NHzSW3BUSU6JRWK=
GB-1 NHG3OFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rEPGlEPTB;MD6xOlQzPCEQvF2= M{XPdXNCVkeHUh?=
KARPAS-422 NYHMZ4s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMU[1O|Qh|ryP NWLXSotzW0GQR1XS
ATN-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLCTWM2OD1yLkG2OlU3KM7:TR?= MUPTRW5ITVJ?
HLE NXnNSnJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMU[4O|ch|ryP MnzqV2FPT0WU
D-542MG M1;aSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTGTWM2OD1yLkG2PVg3KM7:TR?= NGDhTZdUSU6JRWK=
EB-3 M4PPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD1yLkG3N|Eh|ryP MonGV2FPT0WU
HCC1143 M4rmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFdIlQUUN3ME2wMlE4Ozl4IN88US=> MVXTRW5ITVJ?
DJM-1 M4i1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XZemlEPTB;MD6xO|Q2OSEQvF2= NYDwNmlYW0GQR1XS
BT-474 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrMTWM2OD1yLkG3OFg6KM7:TR?= NXHmOFl6W0GQR1XS
BB65-RCC MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn1cZNKSzVyPUCuNVc2PDVizszN NG\FRVVUSU6JRWK=
NCI-H292 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjNTWM2OD1yLkG3OlAyKM7:TR?= MorLV2FPT0WU
MKN28 NHvITnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7SfFV2UUN3ME2wMlE4PjV|IN88US=> MYPTRW5ITVJ?
TK10 M1r0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMUe3NFIh|ryP M3[ydHNCVkeHUh?=
TYK-nu MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[xTWM2OD1yLkG3PVQ6KM7:TR?= MYXTRW5ITVJ?
8305C MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMUe5O|Eh|ryP M{j1NnNCVkeHUh?=
MV-4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TWUmlEPTB;MD6xO|k4PyEQvF2= MW\TRW5ITVJ?
NCI-H522 M1XpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[zTWM2OD1yLkG4NFk1KM7:TR?= MkXxV2FPT0WU
Hs-578-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yz[GlEPTB;MD6xPFI6OiEQvF2= MnLhV2FPT0WU
LCLC-103H MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjYdmVFUUN3ME2wMlE5PTJ5IN88US=> NH;kXnhUSU6JRWK=
MHH-ES-1 NHXnXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLkRo1nUUN3ME2wMlE5PjJ7IN88US=> MWDTRW5ITVJ?
NCI-H441 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;0ZmlEPTB;MD6xPVE1QCEQvF2= MV\TRW5ITVJ?
AM-38 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\iTWM2OD1yLkG5NlI2KM7:TR?= M1T3OnNCVkeHUh?=
SW1783 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76Vmo{UUN3ME2wMlE6OzB3IN88US=> NYHOb3R4W0GQR1XS
SK-HEP-1 NXvWdZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHuTWM2OD1yLkG5OlM4KM7:TR?= MoPFV2FPT0WU
OAW-28 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSzPJpKSzVyPUCuNlAyPzhizszN NIjQfJFUSU6JRWK=
TE-15 NIPtW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXzS5hKSzVyPUCuNlAzPTJizszN NYL6d|B6W0GQR1XS
HCE-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnDc3dKSzVyPUCuNlAzQDRizszN M2TGbXNCVkeHUh?=
JiyoyeP-2003 NGDKVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELHeWxKSzVyPUCuNlA{OzZizszN MXjTRW5ITVJ?
OVCAR-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jaeGlEPTB;MD6yNFYzQCEQvF2= NG\iVIpUSU6JRWK=
SNU-449 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMkC3PVch|ryP NVLV[JVHW0GQR1XS
SBC-5 M{LhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe1ZXlKSzVyPUCuNlEzOTVizszN NF7CRVdUSU6JRWK=
T84 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vxcGlEPTB;MD6yNVI1QCEQvF2= NYjZOIN6W0GQR1XS
LP-1 NXPDdlhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7CNHdKSzVyPUCuNlE{ODJizszN MUXTRW5ITVJ?
MG-63 Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz0TWM2OD1yLkKxN|gzKM7:TR?= M4HC[HNCVkeHUh?=
OAW-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMkG0O|gh|ryP NXi0V3lIW0GQR1XS
L-540 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLzbI1KSzVyPUCuNlE2QThizszN NH\ndmJUSU6JRWK=
RH-1 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISwRXFKSzVyPUCuNlIzPDJizszN NFrBb3pUSU6JRWK=
HCT-15 NIjpUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TvcWlEPTB;MD6yNlQ5PCEQvF2= MnrFV2FPT0WU
OCUB-M NUHaeoFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fUV2lEPTB;MD6yNlQ5QCEQvF2= MkT3V2FPT0WU
GP5d MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K3V2lEPTB;MD6yNlUzQCEQvF2= NHGxO|NUSU6JRWK=
NCI-H2030 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMkK3N|Qh|ryP MlnCV2FPT0WU
ML-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMkK4PFkh|ryP NYfpeopKW0GQR1XS
CAL-39 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDpTWM2OD1yLkKyPVM3KM7:TR?= M{\QOHNCVkeHUh?=
MIA-PaCa-2 M3\4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyxXHBKSzVyPUCuNlMzQDdizszN M2fsVHNCVkeHUh?=
TE-9 M4LxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2njWWlEPTB;MD6yN|MzKM7:TR?= MXfTRW5ITVJ?
LB2518-MEL NY\vRndoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTDTWM2OD1yLkKzN|czKM7:TR?= NHvlfWxUSU6JRWK=
DB NV\6TIU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW2TWM2OD1yLkKzOFM5KM7:TR?= NIHSWmhUSU6JRWK=
NCI-H596 M1P6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M132WmlEPTB;MD6yN|U4OSEQvF2= NWm2[IdzW0GQR1XS
SW1990 M1fFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TFPWlEPTB;MD6yN|k1PiEQvF2= NIfZTXFUSU6JRWK=
P30-OHK NUD2U|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMkSwOUDPxE1? NFmxVIhUSU6JRWK=
ALL-PO M3\pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnBO4RKSzVyPUCuNlQyPjlizszN MVnTRW5ITVJ?
Saos-2 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHEeG1KSzVyPUCuNlQ2PzFizszN M2OwbXNCVkeHUh?=
MFH-ino NGTWb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMkS2PVIh|ryP Mn23V2FPT0WU
OE33 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PjZ2lEPTB;MD6yOVEyKM7:TR?= Mn7mV2FPT0WU
Calu-3 NX7aUldZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTTRW1KSzVyPUCuNlUzQTdizszN M3LifnNCVkeHUh?=
HT NEHreWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMkW2NlEh|ryP MXnTRW5ITVJ?
LXF-289 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXteGdRUUN3ME2wMlI2QTh2IN88US=> MYjTRW5ITVJ?
KGN MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMk[wPFkh|ryP NGT3cpBUSU6JRWK=
NCI-H1417 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMk[1NlQh|ryP NGjjcVhUSU6JRWK=
SF126 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDwTWM2OD1yLkK3N|AzKM7:TR?= M3HQS3NCVkeHUh?=
SAS NXXIdIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMkezNFgh|ryP MVnTRW5ITVJ?
22RV1 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjhSFBKSzVyPUCuNlc{PzhizszN MXrTRW5ITVJ?
GI-1 NYnJNol3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMke0PFch|ryP NEG5U2tUSU6JRWK=
ES3 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH6OZNKSzVyPUCuNlc4PjNizszN NGq2NZFUSU6JRWK=
NB1 NVG4VVg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rDU2lEPTB;MD6yO|g4PiEQvF2= M4TaNnNCVkeHUh?=
NCI-H650 NIDvWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPyc5VKSzVyPUCuNlg{ODJizszN NWnqTGxSW0GQR1XS
IST-MES1 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMki1OVQh|ryP NWPhc5ByW0GQR1XS
UM-UC-3 NYL2emVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHEXow1UUN3ME2wMlI6OTRizszN MlfYV2FPT0WU
CAL-120 NWiwdGVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z1fWlEPTB;MD6yPVY{OSEQvF2= M1nNV3NCVkeHUh?=
UACC-62 NUHsVnVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT5bFVKSzVyPUCuN|AzPDFizszN M{e5dnNCVkeHUh?=
TE-11 NFrFZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwM{CyOFkh|ryP NX\kT2VoW0GQR1XS
MKN1 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwM{CzOkDPxE1? NWmwbVhKW0GQR1XS
KS-1 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojKTWM2OD1yLkOwOVI3KM7:TR?= NXzwXFFIW0GQR1XS
GCIY M1nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H2TWlEPTB;MD6zNVAxOiEQvF2= NXfrfHVyW0GQR1XS
OVCAR-5 M3v4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDiTWM2OD1yLkOxNVA3KM7:TR?= M1Pq[XNCVkeHUh?=
U-266 NWX4eG5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK2eYJKSzVyPUCuN|EyPDdizszN MUfTRW5ITVJ?
Calu-1 M1zVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6zWYJ2UUN3ME2wMlMyOjh7IN88US=> NGfUdJpUSU6JRWK=
SK-LMS-1 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwM{G0Nlkh|ryP NHzqcpJUSU6JRWK=
COLO-741 M2\Qbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jVZWlEPTB;MD6zNVYyPCEQvF2= M4XuenNCVkeHUh?=
RPMI-8226 NF3Z[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnsXm9PUUN3ME2wMlMyPjRzIN88US=> M1rhSnNCVkeHUh?=
KM12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1yLkOxPFMh|ryP NHTvfGtUSU6JRWK=
NMC-G1 NXi0RmpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwM{G4OkDPxE1? MXXTRW5ITVJ?
SJRH30 M1faUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[2TWM2OD1yLkOyNFUzKM7:TR?= MWjTRW5ITVJ?
COR-L105 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTkVJlnUUN3ME2wMlMzOjF6IN88US=> NXn4TJhrW0GQR1XS
IM-9 NGW0enRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rDemlEPTB;MD6zN|AzOSEQvF2= NX36SVZ{W0GQR1XS
TE-12 NWLFUGtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i3XGlEPTB;MD6zN|MyPyEQvF2= NXe1dlZLW0GQR1XS
KG-1 NY\3TY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLmSIlYUUN3ME2wMlM{PDN{IN88US=> MVnTRW5ITVJ?
U251 NI\VZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIThfJBKSzVyPUCuN|M1PTZizszN Mn7BV2FPT0WU
EFO-27 NYnudHR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH2RoVNUUN3ME2wMlM{QTVzIN88US=> MmT5V2FPT0WU
EW-24 NGrDVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrpTWM2OD1yLkOzPVg1KM7:TR?= MonaV2FPT0WU
SF295 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzNmdWUUN3ME2wMlM{QTl7IN88US=> MUnTRW5ITVJ?
MC-IXC NVzzVZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\5OJNKSzVyPUCuN|Q2KM7:TR?= M1ftbnNCVkeHUh?=
NCI-H2405 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n0VGlEPTB;MD6zOFc{OiEQvF2= M2fRcnNCVkeHUh?=
NCI-H2009 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2POb2lEPTB;MD6zOFc{QSEQvF2= MYfTRW5ITVJ?
LB1047-RCC M4OyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LGT2lEPTB;MD6zOVgyPSEQvF2= NV7HfFV3W0GQR1XS
KNS-81-FD MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvjOIxKSzVyPUCuN|Y3PjdizszN M2L4[HNCVkeHUh?=
HOP-92 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwM{[4N{DPxE1? Ml7oV2FPT0WU
L-428 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PCRmlEPTB;MD6zO|AyPiEQvF2= Moe1V2FPT0WU
C3A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPFPG9KSzVyPUCuN|c{PzlizszN NHvUOXdUSU6JRWK=
NCI-H1792 NYmzT49XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLuO49pUUN3ME2wMlM4PjV3IN88US=> MUXTRW5ITVJ?
HuH-7 NHWxbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qzXGlEPTB;MD6zO|kyKM7:TR?= NXrFNFNYW0GQR1XS
AGS NFP3cpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Tvc2lEPTB;MD6zPFY{QCEQvF2= NX;3d5RuW0GQR1XS
HT-1197 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGzZ2hTUUN3ME2wMlM6PDZizszN NInzOZlUSU6JRWK=
CGTH-W-1 M2HUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e4RmlEPTB;MD6zPVkyOyEQvF2= M2f0UXNCVkeHUh?=
KNS-42 NEDRcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\HSIVKSzVyPUCuOFAxPDVizszN Mkn6V2FPT0WU
HuO-3N1 NVW0TGtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jrXmlEPTB;MD60NFA2PSEQvF2= NIra[XpUSU6JRWK=
VMRC-RCZ NWfGSGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor1TWM2OD1yLkSwN|A{KM7:TR?= NULmTI1UW0GQR1XS
SW954 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHNTWM2OD1yLkSwN|M2KM7:TR?= MorYV2FPT0WU
MES-SA NUnUXYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS1SVZrUUN3ME2wMlQxPTB3IN88US=> NETLbYRUSU6JRWK=
Ca-Ski NWX0O5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljoTWM2OD1yLkSwOVI1KM7:TR?= NIHuWVhUSU6JRWK=
SW13 NIrZcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XEbmlEPTB;MD60NFYzPiEQvF2= MkP0V2FPT0WU
NCI-H1437 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLOTWM2OD1yLkSwPFA2KM7:TR?= NUe5SYc4W0GQR1XS
U-118-MG NXSxO4JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNEC5NFQh|ryP M4PKVHNCVkeHUh?=
NCI-H1734 NF3idm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7YNm5KSzVyPUCuOFIxOTNizszN M3nufnNCVkeHUh?=
HDLM-2 NXr0T2JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFns[oNKSzVyPUCuOFIxOzNizszN MoroV2FPT0WU
AU565 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwNEK0Olgh|ryP M1naUXNCVkeHUh?=
FADU MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwNEK2OFkh|ryP MYLTRW5ITVJ?
OS-RC-2 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli2TWM2OD1yLkSzNFg{KM7:TR?= NXOwRWtPW0GQR1XS
CAMA-1 NUHqUHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwNEO2NlYh|ryP NWHCSIpUW0GQR1XS
MONO-MAC-6 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOZopSUUN3ME2wMlQ{QDR7IN88US=> NILNdlZUSU6JRWK=
LB831-BLC NGO3NJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNESzO|Eh|ryP NFHtVI9USU6JRWK=
SW982 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HLWWlEPTB;MD60OFUzQCEQvF2= M2\sXXNCVkeHUh?=
SCC-3 NIjUfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH2TWM2OD1yLkS0OVc6KM7:TR?= MW\TRW5ITVJ?
C32 NYDqNFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[2S2lEPTB;MD60OVIzQSEQvF2= NIXsXIRUSU6JRWK=
BFTC-909 NIPNeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLERVZ[UUN3ME2wMlQ2Ojl7IN88US=> MlX4V2FPT0WU
MEG-01 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwNEWzO|Mh|ryP NYW5VXlvW0GQR1XS
M14 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLVSGpCUUN3ME2wMlQ2QTd7IN88US=> M2DGVXNCVkeHUh?=
MPP-89 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHBfIFDUUN3ME2wMlQ3OjV4IN88US=> NGr3[XZUSU6JRWK=
HCC1937 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof3TWM2OD1yLkS2N|g1KM7:TR?= NFnrOWJUSU6JRWK=
SW837 NGjtWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16zbWlEPTB;MD60OlczOiEQvF2= NIDoSmxUSU6JRWK=
DU-145 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjEWmdKSzVyPUCuOFY4OjlizszN NFSwdJdUSU6JRWK=
LB996-RCC MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljSTWM2OD1yLkS3NFU1KM7:TR?= M3LWUXNCVkeHUh?=
C8166 NF7CeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTBTWM2OD1yLkS3OEDPxE1? NYDRSZgyW0GQR1XS
MOLT-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3vUlJKSzVyPUCuOFc4OzRizszN NVHBRlBuW0GQR1XS
DMS-53 NF7X[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwNEe4NFkh|ryP MYfTRW5ITVJ?
TE-5 NYja[5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPySW1KSzVyPUCuOFg{ODVizszN NHHnSXlUSU6JRWK=
KYSE-520 NF\yN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNEizOFMh|ryP MXvTRW5ITVJ?
Detroit562 M2roe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7FcXU6UUN3ME2wMlQ5QDZizszN NFjDb2RUSU6JRWK=
SIMA NH7JV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[xTWM2OD1yLkS5OFE4KM7:TR?= MXPTRW5ITVJ?
NCI-H1651 NWnqR4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHQcINuUUN3ME2wMlQ6PjdizszN MWfTRW5ITVJ?
HCC1599 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwNEm5OVUh|ryP NH;qW3NUSU6JRWK=
ABC-1 NYfoZ45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XkUmlEPTB;MD61NFQ6PiEQvF2= NWTjNWlDW0GQR1XS
CAL-33 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInMRW5KSzVyPUCuOVA5PDRizszN NX;uU3BOW0GQR1XS
OPM-2 NVvz[XdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNUC5N|ch|ryP NFjaNFdUSU6JRWK=
RPMI-7951 NELhVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrqPYhKSzVyPUCuOVA6PTdizszN Mnf1V2FPT0WU
HT-1080 M1XxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHmxWGhKSzVyPUCuOVEyOTlizszN NIDB[m1USU6JRWK=
LC4-1 M1KwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofDTWM2OD1yLkWxOFA{KM7:TR?= NX3tZYJxW0GQR1XS
OVCAR-3 NF3RRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPVohKSzVyPUCuOVE2PyEQvF2= MVLTRW5ITVJ?
CAPAN-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfXT4lmUUN3ME2wMlUzOjh6IN88US=> NV7UXlNIW0GQR1XS
SK-OV-3 NHzrPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNUK0N|Qh|ryP MXrTRW5ITVJ?
HuP-T3 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Xs[mlEPTB;MD61NlgzPyEQvF2= NHjwOZVUSU6JRWK=
NCI-H838 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvWc2VyUUN3ME2wMlUzQDR7IN88US=> NGnj[HlUSU6JRWK=
K5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwNUOyNFEh|ryP MVHTRW5ITVJ?
CAL-72 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjvTWM2OD1yLkWzN|g4KM7:TR?= NXvCclVNW0GQR1XS
NH-12 M{LGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwNUO5OVkh|ryP M1;uUXNCVkeHUh?=
SNB75 NIP2R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lmc2lEPTB;MD61OVc{KM7:TR?= MXPTRW5ITVJ?
BPH-1 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzQTWM2OD1yLkW2N|Q1KM7:TR?= NHuydG5USU6JRWK=
NOMO-1 M2nNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;GV|QyUUN3ME2wMlU3Ozd{IN88US=> NELOdJdUSU6JRWK=
G-402 M17mPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17a[mlEPTB;MD61OlQ6QSEQvF2= MYLTRW5ITVJ?
NCI-H2052 M3HWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPqR4RKSzVyPUCuOVY4PDFizszN NIHOUGRUSU6JRWK=
RCM-1 M1;HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\FTWM2OD1yLkW3NVY3KM7:TR?= NEXUXI9USU6JRWK=
COR-L279 M4XHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\KXplKSzVyPUCuOVcyQDVizszN NYXZcXhCW0GQR1XS
A253 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\0UXRKSzVyPUCuOVc2OjVizszN M1PlTHNCVkeHUh?=
SK-MM-2 M4O4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNUe2O|kh|ryP NE[z[3BUSU6JRWK=
NCI-H1703 NHjMNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTGTWM2OD1yLkW5OFI4KM7:TR?= M1vXSHNCVkeHUh?=
UACC-257 NFPUOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNUm0PFch|ryP NITnc2pUSU6JRWK=
KALS-1 M3LZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjDcYRKSzVyPUCuOlAxOTFizszN NF7P[VBUSU6JRWK=
ES5 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn1[XpqUUN3ME2wMlYxPDhizszN NXLDWVZXW0GQR1XS
MHH-CALL-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\R[VBkUUN3ME2wMlYxQDh6IN88US=> M{DpfnNCVkeHUh?=
ChaGo-K-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNkGyNlkh|ryP M3v2WXNCVkeHUh?=
TGBC1TKB M3n0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zCe2lEPTB;MD62NVk5KM7:TR?= NWXsTmlXW0GQR1XS
KU-19-19 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwNkS1PFYh|ryP MUnTRW5ITVJ?
COLO-684 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7C[ms2UUN3ME2wMlY2PjFzIN88US=> NELWfnpUSU6JRWK=
LS-1034 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHtTWM2OD1yLk[1PFE6KM7:TR?= MoTKV2FPT0WU
RT-112 M2jjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwNk[1PFch|ryP NUTaS5lpW0GQR1XS
Capan-2 NIjwelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknHTWM2OD1yLk[2OlIzKM7:TR?= MULTRW5ITVJ?
HSC-4 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\XTWM2OD1yLk[2Olk5KM7:TR?= M{\DbnNCVkeHUh?=
COLO-824 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNke4NlMh|ryP MkXqV2FPT0WU
NCI-H2170 NHi1Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSwTWM2OD1yLk[4NlU5KM7:TR?= M2DkT3NCVkeHUh?=
GDM-1 M13MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH6R4VKSzVyPUCuOlg1QTRizszN NYrWeJNMW0GQR1XS
KP-4 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPCfGRKSzVyPUCuOlk2PzNizszN NIDqSG1USU6JRWK=
VA-ES-BJ MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDMT3FDUUN3ME2wMlY6QTh4IN88US=> M2LDNnNCVkeHUh?=
KM-H2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPTblVKSzVyPUCuO|AxQTFizszN NXi2Smp2W0GQR1XS
HH M3;Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwN{C2OlIh|ryP NFHadJNUSU6JRWK=
DK-MG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwN{GwNVYh|ryP NXi3cINyW0GQR1XS
VM-CUB-1 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fMNWlEPTB;MD63NVI2QSEQvF2= NGHzcpVUSU6JRWK=
COLO-829 NEHR[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXFNXNoUUN3ME2wMlcyQTh3IN88US=> NWnPcnFlW0GQR1XS
OMC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzBRZJKSzVyPUCuO|IyODRizszN Ml;0V2FPT0WU
NB12 NIf0c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq1OmkyUUN3ME2wMlczPTB2IN88US=> M{DndXNCVkeHUh?=
NCI-H28 M3L3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7GRYQyUUN3ME2wMlc1ODh|IN88US=> MXTTRW5ITVJ?
A673 NVjWVZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfkd3F[UUN3ME2wMlc2OTd5IN88US=> MoPnV2FPT0WU
LB2241-RCC Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPTV4ljUUN3ME2wMlc3ODh5IN88US=> NHHue3hUSU6JRWK=
CCRF-CEM NFHvVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfFdlFtUUN3ME2wMlc4ODV{IN88US=> M{S4R3NCVkeHUh?=
NCI-H510A M37RWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOxNI1KSzVyPUCuO|cyQDZizszN Mnu3V2FPT0WU
SW48 NHyyb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T5U2lEPTB;MD63O|M{OyEQvF2= MYrTRW5ITVJ?
NCI-H2081 NYT0N2hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nENGlEPTB;MD63PFE1PyEQvF2= MVrTRW5ITVJ?
RMG-I M4D5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fHZWlEPTB;MD63PFIyOiEQvF2= NEXtR5pUSU6JRWK=
LU-99A Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqzW4tOUUN3ME2wMlc5PDF|IN88US=> NHvPOm1USU6JRWK=
KP-N-YS M1;PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDaTWM2OD1yLke4PVIyKM7:TR?= NF64OW5USU6JRWK=
MDA-MB-231 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzqZm1iUUN3ME2wMlgxOTNzIN88US=> NEnk[Y5USU6JRWK=
U031 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL6TWM2OD1yLkixOFI{KM7:TR?= M1ix[nNCVkeHUh?=
EVSA-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTiTWM2OD1yLkixOlczKM7:TR?= MoPkV2FPT0WU
MDA-MB-157 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwOEKyO|Eh|ryP NEmzXGZUSU6JRWK=
EHEB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLQTWM2OD1yLkiyNlc3KM7:TR?= MojxV2FPT0WU
KINGS-1 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiwOndKSzVyPUCuPFI2PTVizszN NYX5S3RbW0GQR1XS
23132-87 NYnHdpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MormTWM2OD1yLkiyPFQ{KM7:TR?= NHLXR4FUSU6JRWK=
EFO-21 M3e5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGxSllKSzVyPUCuPFQxQDlizszN Ml\RV2FPT0WU
DOK NV3Lc3l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPnU5RkUUN3ME2wMlg1QCEQvF2= MV7TRW5ITVJ?
NCI-H2171 M2fkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPOTWM2OD1yLki0PVYh|ryP MmXIV2FPT0WU
NCI-SNU-5 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrTXGZPUUN3ME2wMlg2PTdizszN MV;TRW5ITVJ?
SK-N-DZ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z4bGlEPTB;MD64OVk1OyEQvF2= M{jhWnNCVkeHUh?=
SNU-C2B MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwOE[4NFEh|ryP M{Wyc3NCVkeHUh?=
CP66-MEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe4TWM2OD1yLki3NVEh|ryP NWHidVB{W0GQR1XS
SN12C M1TQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwOEi2N|ch|ryP M3rmOnNCVkeHUh?=
A172 NVrQ[GNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInkU|dKSzVyPUCuPFg3QThizszN MlXzV2FPT0WU
NCI-H2347 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwOEi3OVMh|ryP NWjkPVgzW0GQR1XS
NCI-H2228 M3zSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOEmzN|kh|ryP MVnTRW5ITVJ?
SNU-387 NIC2R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUCyOlQh|ryP NWDpXGhPW0GQR1XS
SK-MEL-24 M2jxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwOUGzOFQh|ryP M1PJW3NCVkeHUh?=
MDA-MB-468 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[2ZVZKSzVyPUCuPVE4OyEQvF2= M2nLSXNCVkeHUh?=
NCI-H1694 M3OwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPNPZJKSzVyPUCuPVE5PzZizszN NIrEclVUSU6JRWK=
CCF-STTG1 NGfnd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\5XmtKSzVyPUCuPVI3OzdizszN NIXWSGNUSU6JRWK=
K052 NYe3VJR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHaTWM2OD1yLkm0NFQ4KM7:TR?= NYH5O|VQW0GQR1XS
NCI-H446 NGPvVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC4W|BiUUN3ME2wMlk2ODFizszN M3r5cHNCVkeHUh?=
MFE-280 M1[0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzelBKSzVyPUCuPVYzQTFizszN MlnMV2FPT0WU
KU812 M3;R[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfETWM2OD1yLkm5N|g6KM7:TR?= NYLJXoxwW0GQR1XS
MDA-MB-361 NFnYc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfQTZhKSzVyPUCuPVk4PzdizszN MnzaV2FPT0WU
Raji NUj4ZoozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzPTWM2OD1zLkCyNlY4KM7:TR?= NWn3N4t1W0GQR1XS
TE-6 NWLxOndnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:1TWM2OD1zLkCzOVY3KM7:TR?= MkLYV2FPT0WU
CAL-148 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjFTWM2OD1zLkC0OFQ{KM7:TR?= NX25WFNLW0GQR1XS
NCI-H1963 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDnOFdpUUN3ME2xMlA1PTV|IN88US=> MlfpV2FPT0WU
SK-N-AS NUDGbJpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HyTmlEPTB;MT6wOFY5PSEQvF2= M{iycHNCVkeHUh?=
RERF-LC-MS M2jGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITzN2RKSzVyPUGuNFY{PDlizszN MmHGV2FPT0WU
BEN M{LhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuwSJZKSzVyPUGuNFcyOzdizszN MkCxV2FPT0WU
CAS-1 NXnM[I5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XJTmlEPTB;MT6wPVEzOyEQvF2= MmTqV2FPT0WU
SW780 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13LRmlEPTB;MT6wPVE5OSEQvF2= MXLTRW5ITVJ?
LU-65 NIPjOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e3R2lEPTB;MT6wPVQyKM7:TR?= Mme4V2FPT0WU
D-283MED NXHSW|ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqwbWtTUUN3ME2xMlEzOjd{IN88US=> M2P5V3NCVkeHUh?=
HCC2157 NUTzeHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwMUO2OFIh|ryP MnfTV2FPT0WU
RCC10RGB NF:1WoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT6TWM2OD1zLkG0NFA3KM7:TR?= NF3XWYxUSU6JRWK=
PLC-PRF-5 NVi5bmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXXeGFKSzVyPUGuNVUzOjlizszN MnPYV2FPT0WU
H4 MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLBTWM2OD1zLkG1OFM6KM7:TR?= MXLTRW5ITVJ?
TUR NVvFTJlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwMUW3OVIh|ryP MlHzV2FPT0WU
NCI-H2141 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M334R2lEPTB;MT6xPFk1PiEQvF2= NF63TZdUSU6JRWK=
PFSK-1 M1HqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HUb2lEPTB;MT6yNFU{OiEQvF2= Mn\MV2FPT0WU
SK-MEL-28 M1jMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\yTWM2OD1zLkKzNlIyKM7:TR?= MW\TRW5ITVJ?
SCC-9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3x[GtKSzVyPUGuNlM3PjVizszN MonZV2FPT0WU
T47D NG\F[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzsV|lKSzVyPUGuNlM3QTZizszN M1\0W3NCVkeHUh?=
TCCSUP MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfGTWM2OD1zLkK1NFI6KM7:TR?= M1y4SHNCVkeHUh?=
SU-DHL-1 NXzMXZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L5N2lEPTB;MT6yOVEyQCEQvF2= Moe5V2FPT0WU
HL-60 NYLMOpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ZTWM2OD1zLkK1OVg5KM7:TR?= MWPTRW5ITVJ?
NCI-H1436 M4PNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHhUlNtUUN3ME2xMlI3OTR7IN88US=> MkfoV2FPT0WU
DMS-114 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvnfJlKSzVyPUGuNlY3OzJizszN MV;TRW5ITVJ?
BOKU M1f4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPGTWM2OD1zLkK4NFk2KM7:TR?= MonxV2FPT0WU
MS-1 NGDlTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLjTWM2OD1zLkK5NFY6KM7:TR?= NFvW[2pUSU6JRWK=
NCI-H661 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7FTWM2OD1zLkOwOFc5KM7:TR?= MlPBV2FPT0WU
HT-3 NWfoVWxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXufFhKUUN3ME2xMlMxPTJ7IN88US=> NIS1[21USU6JRWK=
CAL-54 NYPSXotMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPiTWM2OD1zLkOwO|I2KM7:TR?= NHv3VHZUSU6JRWK=
SW1463 NXXBPVRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\sZ2lEPTB;MT6zNVg4OiEQvF2= M2DYV3NCVkeHUh?=
COLO-668 NYOxeWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwM{OwOVYh|ryP MULTRW5ITVJ?
PANC-08-13 M{LhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPYUYJ[UUN3ME2xMlM{QDB|IN88US=> MXTTRW5ITVJ?
BB49-HNC MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPrXGR2UUN3ME2xMlM1ODFizszN NHLmepRUSU6JRWK=
M059J NVLwPJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwM{W4N|Ih|ryP MlTCV2FPT0WU
NCCIT M1fCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;R[3FKSzVyPUGuN|c6QDhizszN NIf6Z4NUSU6JRWK=
LN-405 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuzTWM2OD1zLkO5NlY1KM7:TR?= MnLyV2FPT0WU
UMC-11 M1H3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonoTWM2OD1zLkO5PVk3KM7:TR?= M3mye3NCVkeHUh?=
NB5 M3HZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\zTWM2OD1zLkSxNlI4KM7:TR?= M2nyXXNCVkeHUh?=
TE-441-T NVrpR3NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrjUo5KSzVyPUGuOFI5OTdizszN NVvPPW0yW0GQR1XS
ME-180 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1zLkS0N|kzKM7:TR?= M{LlVnNCVkeHUh?=
HCC70 NH21fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwNE[wPVYh|ryP M33FWHNCVkeHUh?=
no-10 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDzTWM2OD1zLkS2NVgyKM7:TR?= NGHXVYtUSU6JRWK=
JEG-3 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7iWG9[UUN3ME2xMlUxOTN{IN88US=> M1TD[HNCVkeHUh?=
no-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nJd2lEPTB;MT61NFg5OiEQvF2= MVzTRW5ITVJ?
CHP-126 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nT[mlEPTB;MT61OlY6OSEQvF2= MYPTRW5ITVJ?
EGI-1 M3XueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nwPGlEPTB;MT61PFAzPSEQvF2= MmHHV2FPT0WU
D-392MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILnbI5KSzVyPUGuOVk3OyEQvF2= Mni3V2FPT0WU
RT4 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwNUm2N|ch|ryP M3m5NHNCVkeHUh?=
A204 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DuN2lEPTB;MT61PVgxOSEQvF2= MVrTRW5ITVJ?
NCI-H1304 NEHiN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXPcGp1UUN3ME2xMlY{PTlzIN88US=> MnyzV2FPT0WU
Becker MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rGNWlEPTB;MT62OFI1OSEQvF2= M1jOVnNCVkeHUh?=
OE19 NUTjUGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DoNGlEPTB;MT62OVUyQCEQvF2= NHrlbIRUSU6JRWK=
EKVX NVSzZWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuyOI1KSzVyPUGuOlU3OThizszN NGC5PIxUSU6JRWK=
KLE NHT5c5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O5[mlEPTB;MT62OVcyPCEQvF2= MkTjV2FPT0WU
K-562 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwNkewN|ch|ryP MlHXV2FPT0WU
MDA-MB-175-VII NULt[YlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3qTWM2OD1zLk[4PVk4KM7:TR?= M{e5OXNCVkeHUh?=
NCI-H716 NEn2eZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfaTWM2OD1zLk[5N|A1KM7:TR?= M3L3VnNCVkeHUh?=
Caov-3 NGDzc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TFVWlEPTB;MT62PVQyOyEQvF2= MULTRW5ITVJ?
HCC1187 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S1dGlEPTB;MT63NFU1PSEQvF2= NFPjUYxUSU6JRWK=
CAKI-1 NUPlV3Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn32TWM2OD1zLkeyNlkzKM7:TR?= M3m2N3NCVkeHUh?=
MOLT-16 NUXYN3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXXblU4UUN3ME2xMlc{OzB5IN88US=> M{nwbXNCVkeHUh?=
PC-3 NGO4Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfYW29UUUN3ME2xMlc2ODhizszN Mom4V2FPT0WU
DV-90 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITLbYNKSzVyPUGuO|U2QDVizszN MlPKV2FPT0WU
RXF393 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUToVpVyUUN3ME2xMlc4Ojl2IN88US=> MmLQV2FPT0WU
SK-NEP-1 NWHNWJRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwOEKzN|kh|ryP M{XLS3NCVkeHUh?=
HCC1419 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwOEK2PVIh|ryP M2fE[nNCVkeHUh?=
BV-173 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD1zLkiyPVk2KM7:TR?= M4i5UHNCVkeHUh?=
MKN7 M3WxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPhXFhKSzVyPUGuPFkzOiEQvF2= M4DWWnNCVkeHUh?=
LAN-6 M13lZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFwOEm1OVMh|ryP MVXTRW5ITVJ?
Mo-T NXTUN3lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfRfWd3UUN3ME2xMlkxODN7IN88US=> NWDQPVI1W0GQR1XS
HCC1395 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTvTWM2OD1zLkmyPFY{KM7:TR?= MVfTRW5ITVJ?
HC-1 NFLBNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H0S2lEPTB;MT65N|Q4KM7:TR?= NWSxcXZtW0GQR1XS
HPAF-II NEn4ZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwOUS0NVgh|ryP M2DWO3NCVkeHUh?=
CPC-N NV7PVlVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe3UnNKSzVyPUGuPVgxODJizszN NWK3VIExW0GQR1XS
MKN45 M3HwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnPUGdKSzVyPUGuPVkyOTlizszN NYXtc2xEW0GQR1XS
NCI-H1693 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwMEC0N|Mh|ryP MoH6V2FPT0WU
SHP-77 NIrTUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzLTWM2OD1{LkCwOVM{KM7:TR?= MkDSV2FPT0WU
NCI-H1522 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmbGNmUUN3ME2yMlAyPzJ2IN88US=> NEnueFJUSU6JRWK=
SW1573 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3oTWM2OD1{LkCyNkDPxE1? NFfYS2tUSU6JRWK=
DBTRG-05MG MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;PeGlEPTB;Mj6wOlA5PyEQvF2= MnG2V2FPT0WU
SCC-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwMUSzNUDPxE1? NWfhTVRIW0GQR1XS
DMS-153 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnr[oZ7UUN3ME2yMlE3PjZ6IN88US=> MojwV2FPT0WU
MDA-MB-415 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrHTWM2OD1{LkG3OVIh|ryP M1H4TXNCVkeHUh?=
NCI-H2126 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HuSmlEPTB;Mj6yNlg5QCEQvF2= NEL6TYFUSU6JRWK=
MDA-MB-453 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XaWGlEPTB;Mj6yN|MzKM7:TR?= NIDMe5BUSU6JRWK=
U-87-MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGzTWM2OD1{LkK4OVkzKM7:TR?= M161bnNCVkeHUh?=
LNCaP-Clone-FGC NX;TWmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq0d2pKSzVyPUKuN|AyODJizszN NWf3[XU1W0GQR1XS
NCI-H1581 NXXK[FcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm1TWM2OD1{LkOyNVA2KM7:TR?= NWHQW49lW0GQR1XS
BC-3 NVuyOYV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPS3R7UUN3ME2yMlM3PTB7IN88US=> MoGwV2FPT0WU
HCC38 NUPobGhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;6fIZKSzVyPUKuN|g1PDdizszN NHvLN|ZUSU6JRWK=
HCC2218 NUDOXY46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[x[2lEPTB;Mj60NFgxQSEQvF2= NHLzdG5USU6JRWK=
RO82-W-1 NIHJd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPiTWM2OD1{LkSxNlUh|ryP MYrTRW5ITVJ?
C2BBe1 M1\yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTMNJRoUUN3ME2yMlQyPTd6IN88US=> NGH3NoRUSU6JRWK=
LAMA-84 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrqbog{UUN3ME2yMlU4OzZ6IN88US=> NXrCZWV7W0GQR1XS
GMS-10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJwNUe2NVEh|ryP NYLnfJJQW0GQR1XS
GCT M1uxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDjOJF7UUN3ME2yMlU5Pjl2IN88US=> M{fi[3NCVkeHUh?=
SK-CO-1 NYrye4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vrOWlEPTB;Mj62NVY3KM7:TR?= NF\3TYhUSU6JRWK=
NCI-H526 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwNkO0OUDPxE1? M{jXenNCVkeHUh?=
SW1088 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HjcGlEPTB;Mj63O|g{QSEQvF2= MkHxV2FPT0WU
HT55 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHPTWM2OD1{Lke4Olk2KM7:TR?= MVnTRW5ITVJ?
NB10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJwOEG3OFgh|ryP NGi1cGhUSU6JRWK=
UACC-893 M3[ySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vyPGlEPTB;Mj64OVc1QSEQvF2= M4GwS3NCVkeHUh?=
NCI-H1618 M1Lab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILtR4VKSzVyPUKuPFgyPTNizszN NWizSXhlW0GQR1XS
NCI-H1092 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TlOWlEPTB;Mz6wO|gyOiEQvF2= M4DIc3NCVkeHUh?=
SBC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwMEi1OVMh|ryP MkK3V2FPT0WU
NCI-H1623 NUXYOZJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELCOG5KSzVyPUOuNFk{PCEQvF2= NFr4PGtUSU6JRWK=
SiHa NVzleIp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwMUG5O|ch|ryP MXTTRW5ITVJ?
D-263MG M4LZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTvPHRuUUN3ME2zMlE1Pzh6IN88US=> NXLoeo82W0GQR1XS
NCI-H1573 NGO1T4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\tTVNKSzVyPUOuNVk3PDFizszN MlX2V2FPT0WU
NCI-H82 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3MUJlKSzVyPUOuN|Q1OzlizszN MYrTRW5ITVJ?
NCI-H2196 NIO3XodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNwM{WwNFgh|ryP MVfTRW5ITVJ?
MFM-223 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHRRZJKSzVyPUOuN|c{PTFizszN NHnLeYZUSU6JRWK=
COLO-678 NGHidJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LW[2lEPTB;Mz6zPFE5PiEQvF2= NEPhT|VUSU6JRWK=
EW-3 M4nDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLUTWM2OD1|LkSwPVUh|ryP NH\SXYtUSU6JRWK=
MHH-NB-11 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNwNESwOlkh|ryP NY\BNmpEW0GQR1XS
EM-2 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTPdHpQUUN3ME2zMlY{QThizszN MnfUV2FPT0WU
FTC-133 M{fJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNwNkW0OVgh|ryP M{m3RnNCVkeHUh?=
NCI-H209 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXSbphxUUN3ME2zMlY4PjV|IN88US=> NFPz[JVUSU6JRWK=
TGBC24TKB NFz0eHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTHe|lDUUN3ME2zMlY5OzV3IN88US=> NIfHd|VUSU6JRWK=
LC-1F NYS4ZohGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNwN{G3OlQh|ryP MoPrV2FPT0WU
C-4-II NE\SO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf6TWM2OD1|Lke1OlQ{KM7:TR?= NX3oUHRoW0GQR1XS
NCI-H1650 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNwN{i0OVUh|ryP MlrjV2FPT0WU
JVM-2 NGr2T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNwOUO2N|kh|ryP NXHZPYlFW0GQR1XS
CaR-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjEPHBRUUN3ME2zMlk4PjF5IN88US=> MWrTRW5ITVJ?
MDA-MB-134-VI NUOyWFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjubW9KSzVyPUSuNFI6PTJizszN M3HPeHNCVkeHUh?=
NCI-H719 M1q2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPYTWM2OD12LkG1N|g5KM7:TR?= NHSyWVJUSU6JRWK=
GOTO Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\sWlVKSzVyPUSuNlk4ODVizszN NYnlbGhuW0GQR1XS
NCI-N87 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHTXZBDUUN3ME20MlM5QDJzIN88US=> NH\tTJVUSU6JRWK=
NB6 NUHKZnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PS[WlEPTB;ND60NlUxQSEQvF2= M{faT3NCVkeHUh?=
DSH1 M{PXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWSmlEPTB;ND60O|EyPiEQvF2= NH\p[mVUSU6JRWK=
BT-20 M4\OXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTRwNEmwNFIh|ryP NUDJOoxtW0GQR1XS
NCI-H1882 NYe0NItJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTRwNUC1O{DPxE1? M1XMOXNCVkeHUh?=
WM-115 M17ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iyOGlEPTB;ND61NFg5OSEQvF2= MkDCV2FPT0WU
SKG-IIIa NVLGZ2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVezeI9yUUN3ME20MlY4PzdizszN Ml:3V2FPT0WU
NCI-H69 NHLJWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojQTWM2OD12LkewNlc2KM7:TR?= NFG4S29USU6JRWK=
MSTO-211H Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu2PXNKSzVyPUSuPFM2PjVizszN MVnTRW5ITVJ?
Mewo MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3d49KSzVyPUSuPVY{OTNizszN M{\EOHNCVkeHUh?=
GI-ME-N NGHIc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHLXVBrUUN3ME21MlAxPTB7IN88US=> MnHTV2FPT0WU
T98G MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G4[mlEPTB;NT6wOlUxQCEQvF2= MY\TRW5ITVJ?
ECC4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTVwMEmzO|Ih|ryP M{fhTXNCVkeHUh?=
EW-11 M1fPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\FTWM2OD13LkG4NFk6KM7:TR?= NYqye4J3W0GQR1XS
COLO-800 M1XVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTVwMUmzOFkh|ryP M1r2VnNCVkeHUh?=
NCI-H1755 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\3TWM2OD13LkKzNFI4KM7:TR?= MlqzV2FPT0WU
KMS-12-PE Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:yOolKSzVyPUWuN|UxQDVizszN NIjG[mdUSU6JRWK=
HCC1954 NYPmVYRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fBe2lEPTB;NT64OVk4OSEQvF2= NFTwfGhUSU6JRWK=
NCI-H187 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELhOVJKSzVyPUWuPVI6QDlizszN MWfTRW5ITVJ?
LU-165 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj5SFZlUUN3ME21Mlk6ODB{IN88US=> NGnxcWxUSU6JRWK=
YAPC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq4TWM2OD13Lkm5NFY5KM7:TR?= Mn;0V2FPT0WU
LU-139 M1XnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjRNJYxUUN3ME22MlA5OzZ6IN88US=> NVvrdmUyW0GQR1XS
D-502MG NYXa[m53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PSfGlEPTB;Nj6zNlA1PyEQvF2= MUfTRW5ITVJ?
IST-SL1 NFLOWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDxTWM2OD14LkWzPVQ5KM7:TR?= NWPORYFlW0GQR1XS
DG-75 NVvLVY83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HOUmlEPTB;Nj64PFc5PiEQvF2= NGLJVnNUSU6JRWK=
NCI-H1155 M17BXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTZwOUW1PFEh|ryP NWHHOplzW0GQR1XS
EFE-184 NUjKcVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHnTWM2OD15LkOxOlk2KM7:TR?= NGrvSZVUSU6JRWK=
AsPC-1 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\KRnFKSzVyPUeuOFg5ODdizszN NFrafYJUSU6JRWK=
SW948 NIW5RXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fQTmlEPTB;Nz61PFM6PSEQvF2= M2W1ZXNCVkeHUh?=
NCI-H524 NH\pV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\YeI5KSzVyPUmuOVg3OjhizszN M{TyZ3NCVkeHUh?=
KOSC-2 NYnGcpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPMTWM2OD17Lk[yPFM1KM7:TR?= NFjYPYVUSU6JRWK=
T-24 NHLVXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF23W|RKSzVyPUmuPVQ1OTVizszN MXLTRW5ITVJ?
NCI-H748 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFyLk[zPVch|ryP M{PCVHNCVkeHUh?=
NCI-H23 NXfEU4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFyLk[0OFIh|ryP M2q0WnNCVkeHUh?=
UACC-812 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1dndKSzVyPUGxMlcyPyEQvF2= MWLTRW5ITVJ?
SCLC-21H MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjUVmpKSzVyPUGyMlE2PTFizszN M2W2VXNCVkeHUh?=
NCI-SNU-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLmUGczUUN3ME2xN{4yOjV6IN88US=> MXfTRW5ITVJ?
HD-MY-Z MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnxTWM2OD1zND62N|Y{KM7:TR?= NUDxVFhiW0GQR1XS
SK-N-FI NGXoZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF2Lki5NVIh|ryP M4rkc3NCVkeHUh?=
LB647-SCLC M1zWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF3LkexPVUh|ryP Mm\WV2FPT0WU
NCI-H345 NH;G[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnURYZKSzVyPUG3MlM1OyEQvF2= M2HkV3NCVkeHUh?=
NCI-H1563 M{\JSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF6Lke2NFEh|ryP NGfwbmlUSU6JRWK=
RL NXLmZW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe2fGtHUUN3ME2yNU4zPjV4IN88US=> NEnjc5NUSU6JRWK=
KY821 NGDofmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ{LkC1OVMh|ryP NVK3Oo03W0GQR1XS
JVM-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ3LkC0NVMh|ryP M3zES3NCVkeHUh?=
NCI-H1793 M3r2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPS[W4xUUN3ME2yPE42PDl7IN88US=> MoryV2FPT0WU
LU-134-A NEnjbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNyLkKwN|ch|ryP NWP1eWYyW0GQR1XS
NCI-H1395 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDH[Yk5UUN3ME2zNk4zPDNzIN88US=> MmLMV2FPT0WU
NCI-H1993 M1\1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Swc2lEPTB;M{KuPFIyQCEQvF2= M3LMenNCVkeHUh?=
P31-FUJ NIfL[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG0NXRsUUN3ME2zN{41QDl7IN88US=> NUL5[YtIW0GQR1XS
LS-513 NETVXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HwSWlEPTB;M{WuPFg4QSEQvF2= MW\TRW5ITVJ?
SK-MEL-1 M{DyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nqWGlEPTB;NECuN|Q6QSEQvF2= Mn3iV2FPT0WU
SW684 NEfpeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OxSmlEPTB;NEOuPVY3OSEQvF2= MUjTRW5ITVJ?
COR-L88 M4H5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTR2LkC2OlUh|ryP MUTTRW5ITVJ?
NCI-H889 NYfEboFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXFdG1KSzVyPUS1MlAxQDdizszN NFX4SnNUSU6JRWK=
TALL-1 NVPhZoU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR4LkGxPVkh|ryP MWrTRW5ITVJ?
KARPAS-299 M17JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDMSYdXUUN3ME20O{4yQTl|IN88US=> MUjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2
NCT00724841 Terminated Metastatic Melanoma Gemin X|Teva Pharmaceutical Industries June 2008 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID